» Articles » PMID: 20861246

A Double Mutation in Glycoprotein GB Compensates for Ineffective GD-dependent Initiation of Herpes Simplex Virus Type 1 Infection

Overview
Journal J Virol
Date 2010 Sep 24
PMID 20861246
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Herpes simplex virus (HSV) entry into cells is triggered by the binding of envelope glycoprotein D (gD) to a specific receptor, such as nectin-1 or herpesvirus entry mediator (HVEM), resulting in activation of the fusion effectors gB and gH and virus penetration. Here we report the identification of a hyperactive gB allele, D285N/A549T, selected by repeat passage of a gD mutant virus defective for nectin-1 binding through cells that express a gD-binding-impaired mutant nectin-1. The gB allele in a wild-type virus background enabled the use of other nectins as virus entry receptors. In addition, combination of the mutant allele with an epidermal growth factor receptor (EGFR)-retargeted gD gene yielded dramatically increased EGFR-specific virus entry compared to retargeted virus carrying wild-type gB. Entry of the gB mutant virus into nectin-1-bearing cells was markedly accelerated compared to that of wild-type virus, suggesting that the gB mutations affect a rate-limiting step in entry. Our observations indicate that ineffective gD activation can be complemented by hypersensitization of a downstream component of the entry cascade to gD signaling.

Citing Articles

Induction of necroptosis in multinucleated giant cells induced by conditionally replicating syncytial oHSV in co-cultures of cancer cells and non-cancerous cells.

Suzuki T, Uchida H Mol Ther Oncol. 2024; 32(2):200803.

PMID: 38706990 PMC: 11067338. DOI: 10.1016/j.omton.2024.200803.


Seek and destroy: Development of novel viral therapy for EGFR-expressing tumors.

OConnor C, Lathia J Mol Ther Oncol. 2024; 32(1):200776.

PMID: 38596292 PMC: 10915779. DOI: 10.1016/j.omton.2024.200776.


Oncolytic herpes simplex viruses designed for targeted treatment of EGFR-bearing tumors.

Ingusci S, Hall B, Cohen J, Glorioso J Mol Ther Oncol. 2024; 32(1):200761.

PMID: 38596286 PMC: 10869753. DOI: 10.1016/j.omton.2024.200761.


Novel mutations in U24 and gH rescue efficient infection of an HSV vector retargeted to TrkA.

Marzulli M, Hall B, Zhang M, Goins W, Cohen J, Glorioso J Mol Ther Methods Clin Dev. 2023; 30:208-220.

PMID: 37519407 PMC: 10384243. DOI: 10.1016/j.omtm.2023.06.012.


Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4 GBM cells: A proof of principle.

Sanchez Gil J, Dubois M, Neirinckx V, Lombard A, Coppieters N, DArrigo P Mol Ther Oncolytics. 2022; 26:35-48.

PMID: 35784400 PMC: 9217993. DOI: 10.1016/j.omto.2022.06.002.


References
1.
Bzik D, Fox B, DeLuca N, Person S . Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: mutations affecting rate of virus entry and cell fusion. Virology. 1984; 137(1):185-90. DOI: 10.1016/0042-6822(84)90022-9. View

2.
Zhou G, Roizman B . Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A. 2006; 103(14):5508-13. PMC: 1459385. DOI: 10.1073/pnas.0601258103. View

3.
Nicola A, McEvoy A, Straus S . Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J Virol. 2003; 77(9):5324-32. PMC: 153978. DOI: 10.1128/jvi.77.9.5324-5332.2003. View

4.
Avitabile E, Forghieri C, Campadelli-Fiume G . Complexes between herpes simplex virus glycoproteins gD, gB, and gH detected in cells by complementation of split enhanced green fluorescent protein. J Virol. 2007; 81(20):11532-7. PMC: 2045520. DOI: 10.1128/JVI.01343-07. View

5.
Cai W, Gu B, Person S . Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. J Virol. 1988; 62(8):2596-604. PMC: 253689. DOI: 10.1128/JVI.62.8.2596-2604.1988. View